首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
【24h】

Parallel synthesis, molecular modelling and further structure-activity relationship studies of new acylthiocarbamates as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.

机译:新型酰基硫代氨基甲酸酯作为有效的非核苷HIV-1逆转录酶抑制剂的平行合成,分子建模和进一步的结构-活性关系研究。

获取原文
获取原文并翻译 | 示例
           

摘要

The structure-activity relationships (SARs) of acylthiocarbamates (ATCs), a new class of non-nucleoside HIV-1 reverse transcriptase inhibitors, have been expanded. Sixty-six new analogues were prepared by parallel solution-phase synthesis. In general, the potency of new ATCs was better than that of the first series and O-[2-phthalimidoethyl] 4-chlorophenyl(3-nitrobenzoyl) thiocarbamate turned out to be the most potent ATC so far synthesized (EC(50)=1.5nM). Several ATCs were active at micromolar concentrations against HIV-1 strains carrying the RT Y181C mutation and one of them was also moderately active against the K103R variant. Docking simulations were carried out to rationalize the most relevant SARs.
机译:新型非核苷HIV-1逆转录酶抑制剂酰基硫代氨基甲酸酯(ATC)的结构活性关系(SAR)已得到扩展。通过平行溶液相合成制备了六十六种新的类似物。总的来说,新ATC的效能比第一个ATC更好,O- [2-邻苯二甲酰亚胺基乙基] 4-氯苯基(3-硝基苯甲酰基)硫代氨基甲酸酯被证明是迄今为止合成的最有效的ATC(EC(50)= 1.5nM)。几种ATC在微摩尔浓度下对带有RT Y181C突变的HIV-1菌株具有活性,其中之一对K103R变体也具有中等活性。进行了对接模拟以合理化最相关的SAR。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号